Literature DB >> 3315040

Expression of myelomonocytic antigens on chronic lymphocytic leukemia B cells correlates with their ability to produce interleukin 1.

F Morabito1, E F Prasthofer, N E Dunlap, C E Grossi, A B Tilden.   

Abstract

We analyzed the expression of myelomonocytic-associated antigens on lymphocytes from B cell chronic lymphocytic leukemia (B-CLL) patients. Blood mononuclear cells were depleted of monocytes by one-step Percoll density gradient centrifugation and tested for antigen expression by fluorescent microscopy and flow cytometry. The reactivity of patient lymphocytes was as follows: 26 of 31 were positive for CD14 (Myr), 22 of 31 for a monocyte Fc receptor (MFC-1), 22 of 31 for CD11b (C3bi receptor), eight of 31 for CD15 (Leu-M1), five of 18 for CD13 (My 7), seven of 18 for My 9, and five of 30 for Mo 2. The B lymphocytes of B-CLL patients were also tested for the ability to produce interleukin 1 (IL-1) after depletion of monocytes and T lymphocytes. In 13 of 17 cases, B lymphocytes of patients produced IL-1 as detected in a mouse thymocyte proliferation assay and, in selected cases, a radioimmunoassay specific for IL-1 beta. The 13 cases that produced IL-1 were also positive for the expression of one or more myelomonocytic-associated antigens, whereas the four cases that did not produce IL-1 lacked expression of these antigens. In conclusion, the malignant B cells of B-CLL patients frequently express a variety of antigens generally considered specific for myelomonocytic cells, and expression of these antigens is associated with the ability to produce IL-1.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315040

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Anti-immunoglobulin pretreatment induces a calcium-mobilization response to the chemotactic agent N-formylmethionylleucylphenylalanine in Daudi lymphoblastoid cells.

Authors:  C I Kalunta; J S Kaptein; H Niedzin; S J Scott; G H Lee; P M Lad
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

2.  Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.

Authors:  M Aguilar-Santelises; R Magnusson; S B Svenson; A Loftenius; B Andersson; H Mellstedt; M Jondal
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 3.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

4.  CD23 antigen regulation and signaling in chronic lymphocytic leukemia.

Authors:  S Fournier; G Delespesse; M Rubio; G Biron; M Sarfati
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

5.  Increased spontaneous secretion of IL-6 from B cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimmunity.

Authors:  N Lahat; E Aghai; B Maroun; A Kinarty; M Quitt; P Froom
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

6.  Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma.

Authors:  T Wen; H Mellstedt; M Jondal
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

7.  Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia.

Authors:  L Z Rassenti; T J Kipps
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

8.  Genes for interleukin 7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia.

Authors:  J Frishman; B Long; W Knospe; S Gregory; J Plate
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.